Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.  Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in the overall development of AE37 for both breast and prostate cancer indications.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

AE37 is a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine designed to train the immune system, independent of HLA-type, to track down cancer cells throughout the body and destroy them.  The positive interim Phase 2b results, building upon completed pre-clinical and Phase I breast cancer studies, enables Antigen Express to move up the timing of key development and regulatory plans.  In particular, the company will organize an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by the end of Q1 2012.  With the FDA's guidance, the Company will move into a pivotal Phase 3 clinical development program in women with loco-regional breast cancer that express low to moderate levels of HER2.  Parallel steps will be taken with the European Medicines Agency using the same Phase 2b results.  The Phase 2b is currently planned to enroll a total of 300 women and will continue as planned to provide additional valuable information on efficacy and safety of AE37 as the Company pursues its Phase 3 trial plans.

Dr. Eric von Hofe, Ph.D., President of Antigen Express, said: "While the number of patients with recurrent breast cancer is still too low to confirm statistical significance in this ongoing study, the approximate
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... , , MIGDAL HAEMEK, Israel , Feb. ... for modern medicine, as their origins are unclear and the comprehension ... , Applied Spectral Imaging (ASI) a leading provider of ... European Union (EU) to be one out of nine industry and ...
... ... , ... February 16, 2010 -- Akaza Research is pleased to announce its participation in the ... is being held at the Orlando World Center Marriott Resort and is one of ...
... ... for comparison, querying, and sharing of NGS runs; free 2-hour seminar, includes lunch and ... ... Sequencing , , ,Learn about sequence data management and the GenomeQuest interactive, web-based tools ...
Cached Biology Technology:EU Recognizes Importance of ASI's Research on Developing New Smart Imaging Molecular Tools for Combating Neurodegenerative Diseases 2EU Recognizes Importance of ASI's Research on Developing New Smart Imaging Molecular Tools for Combating Neurodegenerative Diseases 3Akaza Research to Present OpenClinica Electronic Data Capture Software at Partnerships in Clinical Trials 2010 2GenomeQuest Announces Boston Seminar: Sequence Data Management for Next Generation Sequencing 2
(Date:4/16/2014)... Florida State University researchers have identified a new syndrome ... density and muscle mass with obesity. , "It used ... the better your bones would be because the bones ... Stiebeling Professor of Nutrition at Florida State. "But, that,s ...
(Date:4/16/2014)... known as Kennedy,s disease, spinal and bulbar muscular atrophy (SBMA) ... muscle weakness and atrophy. Researchers have long considered it to ... cells in the spinal cord and brainstem that control muscle ... April 16, 2014 online issue of Neuron , a ...
(Date:4/16/2014)... do all of our movements, thoughts and feelings ... recent studies have suggested that some of the conversations might ... may be listening in on, or even participating in, some ... astrocytes might only be tuning in part of the time ...
Breaking Biology News(10 mins):Researchers: Obesity can amplify bone and muscle loss 2Mutant protein in muscle linked to neuromuscular disorder 2Eavesdropping on brain cell chatter 2Eavesdropping on brain cell chatter 3
... College of Medicine have discovered how the mutated huntingtin gene ... Huntington,s disease. The report of their findings is available in ... to show that the mutated huntingtin gene activates a particular ... further, to show what effect activation of that enzyme has ...
... DC - A protein known to play a role ... have a mixed function in breast cancer development, say ... University Medical Center (GUMC). The findings, presented at ... DC, indicate that the function of this protein, known ...
... Sophisticated sensors that measure leaf wetness, soil moisture ... Springbrook World Heritage precinct in south-east Queensland. ... uncover the microclimatic conditions favourable for rapid natural ... of ten sensor nodes, connected wirelessly, has been ...
Cached Biology News:Huntington's disease deciphered 2Huntington's disease deciphered 3Dual role in breast tissue for a protein involved in leukemia 2Rainforest rehab in every sense 2
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
Request Info...
Biology Products: